Point Biopharma up on enrollment completion for cancer therapy trial

POINT Biopharma Global

12/01/2023 16:41

** Shares of Point Biopharma Global Inc  PNT.O  gain ~3% to
$7.45 
    ** Co says it has completed enrollment for randomization
phase of a late-stage study for its experimental therapy,
PNT2002, to treat a type of prostate cancer  
    ** Encouraged that timing for the trial remains on track,
illustrating Point's ability to execute clinically and to
"develop and bring forth a potentially practice-changing
therapy" - William Blair analyst Andy Hsieh 
    ** Results from the study expected in mid-2023, which if
successful would help validate the company's platform - Hsieh
    ** PNT shares up ~30% in the past 12 months 
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))